Osimertinib
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].
Product Specifications
CAS Number
[1421373-65-0]
Product Name Alternative
AZD-9291; Mereletinib
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/AZD-9291.html
Purity
99.99
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
Molecular Formula
C28H33N7O2
Molecular Weight
499.61
Precautions
H302, H315, H319, H335
References & Citations
[1]Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4 (9) :1046-61.|[2]Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. Mol Cancer Ther. 2018 Apr;17 (4) :740-750.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
EGFR/ErbB1/HER1
Citation 01
ACS Nano. 2022 Aug 23;16 (8) :12590-12605.|Acta Chromatogr. 2025 Jan 07.|Acta Pharmacol Sin. 2019 Dec;40 (12) :1587-1595.|Acta Pharmacol Sin. 2021 Apr;42 (4) :648-654.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Acta Pharmacol Sin. 2025 Apr;46 (4) :1045-1057.|Adv Mater. 2025 May 22:e2504050.|Adv Sci (Weinh) . 2024 Dec 16:e2411479.|Adv Sci (Weinh) . 2024 Jul;11 (26) :e2306348.|Adv Sci (Weinh) . 2025 Jun 23:e03322.|Adv Ther. 2024 Jul 18.|Am J Cancer Res. 2023 Sep 15;13 (9) :4145-4162.|Am J Transl Res. 2021 Jun 15;13 (6) :6055-6065.|Anticancer Res. 2024 Oct;44 (10) :4175-4188.|Anticancer Res. 2019 Sep;39 (9) :4817-4828.|Appl Surf Sci. 2024 Dec 21.|Basic Clin Pharmacol Toxicol. 2025 Dec;137 (6) :e70143.|Biochem Biophys Res Commun. 2024 Sep 19:733:150711.|Biochem Pharmacol. 2025 Jul 29;242 (Pt 1) :117198.|Biochem Pharmacol. 2026 Jan;243 (Pt 2) :117562.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biol Methods Protoc. 2025 Feb 13;10 (1) :bpaf012.|Biomed Pharmacother. 2024 Feb:171:116124.|Bioorg Chem. 2023 Jun:135:106494.|Bioorg Chem. 2025 Aug 9:164:108864.|bioRxiv. 2023 Oct 27:2023.10.26.563996.|bioRxiv. 2024 Feb 12.|bioRxiv. 2025 Apr 9.|bioRxiv. 2025 January 21.|bioRxiv. 2025 Oct 17.|BMC Cancer. 2025 Apr 8;25 (1) :641.|Cancer Cell Int. 2021 Apr 15;21 (1) :216.|Cancer Cell Int. 2021 Jul 3;21 (1) :337.|Cancer Cell. 2025 Jul 25:S1535-6108 (25) 00310-1.|Cancer Discov. 2019 Jul;9 (7) :926-943.|Cancer Gene Ther. 2023 Jan;30 (1) :149-162.|Cancer Lett. 2025 Apr 10:217715.|Cancer Res Treat. 2023 Jul;55 (3) :778-803.|Cancer Res. 2023 Jul 5;83 (13) :2187-2207.|Cancer Res. 2023 May 2;83 (9) :1490-1502.|Cancer Res. 2024 Feb 1;84 (3) :479-492.|Cancer Res. 2025 Feb 1;85 (3) :585-601.|Cancer Res. 2025 Nov 6.|Cancers. 2019 Jul 5;11 (7) :947.|Cancers. 2019 Oct 14;11 (10) :1550.|Cell Chem Biol. 2018 Aug 16;25 (8) :996-1005.e4.|Cell Death Differ. 2024 Sep;31 (9) :1140-1156.|Cell Death Dis. 2019 Aug 13;10 (8) :615.|Cell Death Dis. 2025 May 25;16 (1) :414.|Cell Death Dis. 2019 May 1;10 (5) :361. |Cell Oncol (Dordr) . 2022 Oct;45 (5) :951-965.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Cell Rep Med. 2024 Mar 19;5 (3) :101471.|Cell Rep. 2024 Oct 8;43 (10) :114812.|Clin Cancer Res. 2025 Jun 4:OF1-OF17.|Commun Biol. 2021 Dec 13;4 (1) :1391.|Commun Biol. 2025 Nov 29.|Cytotechnology. 2025 Feb;77 (1) :23.|Dev Cell. 2025 May 15:S1534-5807 (25) 00287-4.|Discov Oncol. 2025 Aug 12;16 (1) :1541.|Drug Deliv Transl Res. 2022 Oct;12 (10) :2474-2487.|Drug Metab Pharmacokinet. 2020 Oct;35 (5) :456-465.|Ecotoxicol Environ Saf. 2025 Nov 15:307:119433.|Environ Toxicol. 2019 Apr;34 (4) :476-485. |Eur J Drug Metab Pharmacokinet. 2021 Sep;46 (5) :625-635.|Eur J Pharmacol. 2021 Sep 15:907:174297.|Exp Hematol Oncol. 2024 Oct 1;13 (1) :97.|Faculty of Medicine. University of Oslo. 2019 Feb.|Free Radic Biol Med. 2025 Aug 9:240:267-283.|Front Biosci (Landmark Ed) . 2025 Sep 25, 30 (9), 40454.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Genes (Basel) . 2024 Dec 19;15 (12) :1624.|Genes Cancer. 2017 Mar;8 (3-4) :497-504.|Genes Genomics. 2025 Mar;47 (3) :331-340.|Heart Rhythm. 2025 Jul 11:S1547-5271 (25) 02640-2.|Int Immunopharmacol. 2024 Jan 5:126:111265.|Int Immunopharmacol. 2026 Jan 1;168 (Pt 1) :115795.|Int J Anal Chem. 2020 Dec 28:2020:8814214.|Int J Biol Macromol. 2024 May;268 (Pt 1) :131560.|Int J Biol Sci. 2021 Apr 12;17 (7) :1671-1681.|Int J Mol Med. 2023 Nov;52 (5) :102.|Int J Mol Med. 2025 Dec;56 (6) :217.|Int J Mol Sci. 2023 May 15;24 (10) :8794.|Int J Nanomedicine. 2025 Aug 27:20:10389-10405.|Int J Oncol. 2020 Jan;56 (1) :243-257.|Int J Pharm. 2025 Dec 25:686:126358.|J Biol Chem. 2023 Jun;299 (6) :104814.|J Cell Physiol. 2022 Mar;237 (3) :1780-1789.|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100.|J Control Release. 2024 Dec:376:829-841.|J Ethnopharmacol. 2024 Jul 18:118586.|J Exp Clin Cancer Res. 2019 Mar 15;38 (1) :129.|J Exp Clin Cancer Res. 2025 Jul 9;44 (1) :197.|J Exp Clin Cancer Res. 2025 Mar 11;44 (1) :95.|J Exp Clin Cancer Res. 2019 Mar 15;38 (1) :129. |J Exp Clin Cancer Res. 2019 May 23;38 (1) :219. |J Med Chem. 2017 Apr 13;60 (7) :2944-2962. |J Med Chem. 2023 Apr 27;66 (8) :5427-5438.|J Med Chem. 2025 Aug 28;68 (16) :17917-17932.|J Nat Med. 2023 Jun;77 (3) :523-534.|J Natl Cancer Inst. 2023 Nov 8;115 (11) :1383-1391.|J Pharm Anal. 2021 Dec;11 (6) :799-807.|Mol Cancer Res. 2019 Feb;17 (2) :499-507. |Mol Cancer Res. 2019 Nov;17 (11) :2233-2243.|Mol Cancer Res. 2024 Nov 1;22 (11) :1051-1063.|Mol Cancer Ther. 2018 Mar;17 (3) :603-613.|Mol Cancer Ther. 2019 May;18 (5) :920-928.|Mol Cancer Ther. 2023 Sep 5;22 (9) :1013-1027.|Mol Cell. 2025 Apr 3;85 (7) :1311-1329.e16.|Mol Med Rep. 2021 Jan;23 (1) :48.|Mol Oncol. 2023 Aug;17 (8) :1648-1665.|Mol Pharmacol. 2022 Jun;101 (6) :381-389.|Nat Cancer. 2022 Apr;3 (4) :402-417.|Nat Cancer. 2023 Jun;4 (6) :829-843.|Neoplasia. 2024 Aug 14:57:101039.|NPJ Precis Oncol. 2025 Nov 26;9 (1) :391.|Oncogene. 2022 May;41 (22) :3104-3117.|Oncogene. 2024 Nov;43 (49) :3556-3569.|Oncogene. 2024 Sep;43 (37) :2781-2794.|Oncogene. 2025 May;44 (19) :1400-1414.|Oncol Lett. 2023 Jul 20;26 (3) :380.|Oncotarget. 2015 Oct 13;6 (31) :31313-22. |Oncotarget. 2016 Oct 25;7 (43) :69760-69769.|Oncotarget. 2017 Mar 14;8 (11) :18359-18372. |Patent. US20190010159A1.|Patent. US20200276189A1.|Patent. US20210315911A1.|Patent. US20230158019A1.|Pharmaceutics. 2024 Nov 12;16 (11) :1444.|Phytomedicine. 2025 Jul 25:143:156788.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Research Square Preprint. 2021 Jul.|Research Square Preprint. 2021 Jun.|Research Square Preprint. 2021 Mar.|Research Square Preprint. 2021 May.|Research Square Preprint. 2023 May 5.|Research Square Preprint. 2024 Dec 02.|Research Square Preprint. 2024 Jan 3.|Research Square Preprint. 2024 Nov 26.|Research Square Print. December 21st, 2022.|Respir Physiol Neurobiol. 2020 Oct;281:103496.|Respir Res. 2024 May 20;25 (1) :215.|RSC Chem Biol. 2023 Aug 29;4 (11) :894-905.|Sci Adv. 2025 Oct 17;11 (42) :eady7930.|SSRN. 2025 Apr 11.|State University of New York at Buffalo. 2025.|Stem Cell Res Ther. 2025 Oct 31;16 (1) :599.|the Scripps Research Institute. 2025.|Theranostics. 2021 Jan 19;11 (7) :3392-3416.|Theranostics. 2021 Mar 24;11 (12) :5650-5674.|Toxicol Appl Pharmacol. 2025 Apr 3:117327.|Transl Lung Cancer Res. 2024 Oct 31;13 (10) :2698-2712.|Transl Lung Cancer Res. 2025 Jun 30;14 (6) :2159-2179.|Universitat Politècnica de València. 2021 Sep.|World J Gastrointest Oncol. 2025 Aug 15;17 (8) :108535.|Cancer Cell. 2020 Jan 13;37 (1) :104-122.e12.|Cancer Lett. 2023 Jul 1:565:216237.|Commun Biol. 2024 Mar 1;7 (1) :250.|Int J Electrochem Sci. 2024 Nov 26.|Mol Oncol. 2025 Jul 18.|Oncotarget. 2017 Dec 6;9 (2) :1641-1655.|Patent. US20250275968A1.|Research Square Preprint. 2023 Jun 30.|Signal Transduct Target Ther. 2025 Nov 28;10 (1) :389.|SSRN. 2025 Sep 25.|Xenobiotica. 2018 Nov;48 (11) :1106-1112.|Research Square Preprint. 2021 May.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
NBP2-54461AF350 0.1 mL
Mouse Monoclonal Ig gamma-4 Chain C Region Antibody (IGHG4/1345) [Alexa Fluor 350]
Ask
View Details 
P4071-76A-ML405 100 µL
PIP5K1A, NT (Phosphatidylinositol-4-phosphate 5-kinase Type-1 alpha, PtdIns (4) P-5-Kinase alpha, PIP5KI-alpha, Phosphatidylinositol-4-phosphate 5-kinase Type I alpha, 68kD Type I Phosphatidylinositol-4-phosphate 5-kinase alpha, PIP5KIalpha) (MaxLight 405) discontinued
Ask
View Details